Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Shanghai Junshi Biosciences Co., Ltd. Class H ( (HK:1877) ) has issued an announcement.
Shanghai Junshi Biosciences Co., Ltd. announced that the U.S. FDA has approved its investigational new drug application for JS212, a bispecific antibody-drug conjugate targeting EGFR and HER3 for advanced solid tumors. This approval marks a significant step in the company’s research and development efforts, potentially enhancing its position in the oncology market by addressing drug resistance and expanding treatment options for a wider range of tumors.
The most recent analyst rating on (HK:1877) stock is a Hold with a HK$34.70 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.
More about Shanghai Junshi Biosciences Co., Ltd. Class H
Shanghai Junshi Biosciences Co., Ltd. is a pharmaceutical company based in China that specializes in the development of innovative drugs, particularly focusing on antibody-drug conjugates for the treatment of various cancers.
Average Trading Volume: 4,544,298
Technical Sentiment Signal: Buy
Current Market Cap: HK$37.15B
For detailed information about 1877 stock, go to TipRanks’ Stock Analysis page.